Is the Minister able to indicate why there might be anxiety about giving priority to safety? Is it because methodology by way of clinical trials evaluation is not sufficiently well developed to make that a statutory principle for the availability of medicinal products or medical devices? Is it that there might be some basis for legal challenge that would make this ill-advised? If not, it appears that putting safety at the forefront is in the interests of patients, our healthcare system, clinicians and the standing of our country as a place to lead in the development of the life sciences.
Medicines and Medical Devices Bill
Proceeding contribution from
Lord Kakkar
(Crossbench)
in the House of Lords on Monday, 26 October 2020.
It occurred during Debate on bills
and
Committee proceeding on Medicines and Medical Devices Bill.
Type
Proceeding contribution
Reference
807 c18GC 
Session
2019-21
Chamber / Committee
House of Lords Grand Committee
Subjects
Librarians' tools
Timestamp
2024-04-29 10:36:34 +0100
URI
http://hansard.intranet.data.parliament.uk/Lords/2020-10-26/20102630000035
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Lords/2020-10-26/20102630000035
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Lords/2020-10-26/20102630000035